The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer.
Akira Fukutomi
Honoraria - Lilly; Taiho Pharmaceutical
Katsuhiko Uesaka
Honoraria - Lilly; Taiho Pharmaceutical
Narikazu Boku
Honoraria - Taiho Pharmaceutical
Hideyuki Kanemoto
No relevant relationships to disclose
Masaru Konishi
No relevant relationships to disclose
Ippei Matsumoto
Honoraria - Lilly
Yuji Kaneoka
No relevant relationships to disclose
Yasuhiro Shimizu
No relevant relationships to disclose
Shoji Nakamori
No relevant relationships to disclose
Hirohiko Sakamoto
No relevant relationships to disclose
Soichiro Morinaga
No relevant relationships to disclose
Osamu Kainuma
No relevant relationships to disclose
Koji Imai
No relevant relationships to disclose
Naohiro Sata
No relevant relationships to disclose
Shoichi Hishinuma
No relevant relationships to disclose
Takayuki Nakamura
No relevant relationships to disclose
Michio Kanai
No relevant relationships to disclose
Satoshi Hirano
Honoraria - Taiho Pharmaceutical
Yukinobu Yoshikawa
Honoraria - Taiho Pharmaceutical
Yasuo Ohashi
Honoraria - Lilly; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical